News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
ONL Therapeutics
NEWS
JOBS
NEWS
Deals
Money on the Move: January 12 – 18
Funds are always flowing in the life science industry. Here’s where the money’s headed this week.
January 18, 2022
·
2 min read
·
Kate Goodwin
BioMidwest
Biopharma Money on the Move: December 16-22
A roundup of the latest biopharma companies scooping up cash through IPOs and financing rounds.
December 23, 2020
·
4 min read
·
Kate Goodwin
IN THE PRESS
BioMidwest
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
January 26, 2023
·
2 min read
Drug Development
AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study
July 12, 2022
·
3 min read
Business
ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer
February 9, 2022
·
4 min read
BioMidwest
ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones
January 13, 2022
·
3 min read
Business
ONL Therapeutics Names Connie Chang as Chief Operating OfficerCompany expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related macular degeneration
January 19, 2021
·
3 min read
BioMidwest
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
December 22, 2020
·
4 min read
BioMidwest
ONL Therapeutics Announces First Patient Treated in Phase I Study with ONL1204ONL Therapeutics transformed into a clinical stage biopharmaceutical company with first-in-human study
October 23, 2019
·
3 min read
BioMidwest
ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases
May 18, 2017
·
3 min read
Business
ONL Therapeutics Strengthens Leadership With Addition To Board Of Directors And Expansion Of Operations Team
March 29, 2017
·
6 min read
BioMidwest
ONL Therapeutics Receives Nearly $1.0 Million Grant From National Eye Institute For Continued Advancement Of ONL1204 Program
March 21, 2017
·
3 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details